Total
0
Shares
Starpharma Holdings (ASX:SPL) - CEO, Dr Jackie Fairley - The Market Herald
CEO, Dr Jackie Fairley
Source: The Australian
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Starpharma (SPL) has signed a research agreement with MSD, the trade name of one of the largest pharmaceutical companies in the world, Merck and Co
  • Under the agreement, MSD will research molecule-based Antibody Drug Conjugates (ADCs) using Starpharma's drug delivery technology, DEP
  • ADCs target specific cells and then releases a drug to destroy it
  • The partnership will explore the potential of DEP technology
  • On the market this morning, Starpharma is up 3.43 per cent and is trading at $2.11 per share

Starpharma (SPL) has signed a research agreement with MSD, the trade name of one of the largest pharmaceutical companies in the world, Merck and Co.

Under the agreement, MSD will research dendrimer-based Antibody Drug Conjugates (ADCs) using Starpharma's DEP technology.

ADCs are antibodies that are linked to one or more drug molecules. When the ADC meets its targeted cell, such as a cancerous cell, the drug is released to kill it.

Starpharma's DEP will work as the "drug delivery" mechanism to ensure the drug is delivered to the right part of the body at the right time.

The partnership will explore the potential of DEP technology to provide improved characteristics to ADCs, such as greater homogeneity, site specific attachment and higher drug antibody ratio.

"MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area," Starpharma CEO Jackie Fairley said.

Notably, DEP technology has already shown significant advantages, such as the DEP HER-2 ADC, which showed significant tumour regression and 100 per cent survival.

Earlier this month, Starpharma reported that AstraZeneca will expand the clinical program for a drug candidate which uses DEP.

On the market this morning, Starpharma is up 3.43 per cent and is trading at $2.11 per share at 11:02 am AEDT.

SPL by the numbers
More From The Market Herald
Palla Pharma (ASX:PAL) raises $12.2M to improve working capital

" Palla Pharma (ASX:PAL) raises $12.2M to improve working capital

Pharmaceutical company Palla Pharma (PAL) has raised roughly $12.24 million via a placement and institutional entitlement offer.
Neurotech (ASX:NTI) - Chairman, Brian Leedman - The Market Herald

" Neurotech (ASX:NTI) looks to bank $3.5M via placement and underwriting exercise

Neurotech (NTI) is set to pocket $3.5 million via an underwritten exercise options shortfall and an oversubscribed private placement.
Emerald Clinics (ASX:EMD) - Managing Director & CEO, Michael Winlo - The Market Herald

" Emyria (ASX:EMD) adds second clinic in Perth

Emyria (EMD) has added a second Emerald Clinic consulting suite in Perth due to strong growth.
Noxopharm (ASX:NOX) - Chief Executive Officer, Dr Graham Kelly - The Market Herald

" Noxopharm (ASX:NOX) banks $4.6M from government R&D rebate

Noxopharm (NOX) has pocketed $4.6 million from the Federal Government’s research and develop (R&D) tax rebate scheme.